Two small defense-tech companies, both riding the same macro tailwind (U.S. military modernization, counter-UAS, space proliferation), but attacking it from completely different angles.
TICKER ............. FEIM PRICE .............. $40.38
SHARES (DIL) ....... 9.84M MARKET CAP ......... $397M
ENTERPRISE VALUE ... $405M FISCAL YR END ...... April 30
NET DEBT ........... $8.0M LAST REPORTED ...... Q3 FY2026 (Jan 31, 2026)FEIM has been public since 1966 — plenty of cycle history. The 10-year window captures one full revenue cycle: a deep trough (FY2018-FY2020) and a strong recovery (FY2024-FY2025). Understanding this cyclicality is essential for setting DCF assumptions, because FEIM’s revenue doesn’t grow linearly — it swings with defense procurement cycles and satellite program timing.
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | LTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55,416 | 50,351 | 39,407 | 49,509 | 41,510 | 54,254 | 48,296 | 40,777 | 55,274 | 69,811 | 67,815 |
| Rev growth | – | -9.1% | -21.7% | +25.6% | -16.2% | +30.7% | -11.0% | -15.6% | +35.6% | +26.3% | -2.9% |
| Gross profit | 20,436 | 11,249 | 5,163 | 15,789 | 5,800 | 16,921 | 8,599 | 7,849 | 18,583 | 30,097 | 25,737 |
| Gross margin | 36.9% | 22.3% | 13.1% | 31.9% | 14.0% | 31.2% | 17.8% | 19.2% | 33.6% | 43.1% | 37.9% |
| SG&A | 13,205 | 11,898 | 10,608 | 12,100 | 11,600 | 13,189 | 11,662 | 9,372 | 10,184 | 12,289 | – |
| R&D | 5,929 | 6,876 | 6,950 | 6,506 | 5,100 | 4,690 | 4,975 | 3,149 | 3,380 | 6,076 | – |
| SBC (memo) | 450 | 457 | 470 | 500 | 350 | 270 | 250 | 200 | 820 | 1,160 | – |
| Op income | 1,302 | (7,525) | (12,395) | (2,817) | (10,900) | (958) | (8,038) | (4,672) | 5,019 | 11,732 | 6,627 |
| Op margin | 2.3% | -14.9% | -31.4% | -5.7% | -26.3% | -1.8% | -16.6% | -11.5% | 9.1% | 16.8% | 9.8% |
| Net income | 1,005 | (4,821) | (23,777) | (2,529) | (10,000) | 680 | (8,663) | (5,501) | 5,594 | 23,802 | 7,180 |
Key observation: Revenue has oscillated between $39M (FY2018 trough) and $70M (FY2025 peak) over the last decade. The business is structurally lumpy — large satellite and defense contracts drive multi-year swings. The FY2025 peak at 43.1% gross margin and 16.8% operating margin represents the best profitability in the company’s recent history, driven by favorable satellite contract mix. The LTM already shows margin normalization back toward 38% gross / 10% operating as new contracts ramp at lower initial margins.
| Metric | 10-Yr Low | Year | 10-Yr High | Year | Current (LTM) | 10-Yr Avg |
|---|---|---|---|---|---|---|
| Gross margin | 13.1% | FY2018 | 43.1% | FY2025 | 37.9% | 24.5% |
| Op margin | -31.4% | FY2018 | 16.8% | FY2025 | 9.8% | -6.9% |
| Net margin | -60.3% | FY2018 | 34.1% | FY2025 | 10.6% | -7.5% |
| FCF margin | -7.3% | FY2019 | 20.1% | FY2021 | -5.6% | 3.1% |
| Revenue growth | -21.7% | FY2018 | +35.6% | FY2024 | -2.9% | +2.9% |
What caused the trough (FY2018-FY2020): Commercial satellite spending collapsed as the old generation of geostationary programs wound down. FEIM was caught in a multi-year gap between the end of legacy GEO programs and the beginning of the proliferated LEO satellite boom. Revenue fell 29% from FY2016 to FY2018. Simultaneously, the company took an $11.2M tax valuation allowance charge in FY2018 and divested its Belgian subsidiary (Gillam).
What caused the peak (FY2024-FY2025): Three simultaneous tailwinds: (1) proliferated satellite constellations created new demand at scale, (2) defense spending on precision timing surged (Golden Dome, counter-UAS, missile defense), and (3) the TURbO miniature atomic clock moved from development to initial production. Revenue grew 71% from the FY2023 trough to FY2025 peak.
Where are we now: Late-cycle. FY2025 margins were peak levels that are already normalizing in FY2026. However, the backlog is at an all-time record ($83M) and the contract pipeline is stronger than ever ($45M in fresh satellite awards). This is unusual — typically margins peak when backlog peaks, but here backlog is still expanding while margins compress. The explanation is contract mix: new proliferated satellite contracts have lower initial margins (higher production rates, lower per-unit pricing) than the legacy GEO business. FEIM is trading margin quality for revenue quantity.
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | LTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | 2,800 | 3,500 | 4,533 | (97) | (1,400) | 12,160 | 4,040 | 1,180 | 8,710 | (1,430) | (900) |
| Capex | (2,000) | (1,500) | (1,418) | (2,767) | (1,500) | (1,240) | (1,860) | (920) | (1,490) | (1,810) | (2,900) |
| Free cash flow | 800 | 2,000 | 3,115 | (2,864) | (2,900) | 10,920 | 2,180 | 260 | 7,220 | (3,240) | (3,800) |
| FCF margin | 1.4% | 4.0% | 7.9% | -5.8% | -7.0% | 20.1% | 4.5% | 0.6% | 13.1% | -4.6% | -5.6% |
| D&A | 3,600 | 3,400 | 2,484 | 2,802 | 3,000 | 3,300 | 3,030 | 2,430 | 2,120 | 2,060 | – |
| ROIC | ~1% | neg | neg | neg | neg | neg | neg | neg | ~7% | ~15% | ~10% |
FCF note: FY2025 FCF was -$3.2M despite $11.7M operating income because of working capital consumption — contract assets (unbilled receivables) surged from $10.5M to $17.9M as revenue was recognized on percentage-of-completion contracts faster than billing. This is timing, not a structural cash drain. FY2024 FCF of $7.2M was the cleanest recent year.
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $32M | $39M | $30M | $37M | $36M | $40M | $42M | $57M | $78M | $70M | $83M |
Backlog has more than doubled from the FY2018 trough ($30M) to the current record ($83M). The March 2026 announcement of $45M in new satellite contracts will push backlog toward $100M+ as those awards enter funded status. Management expects 69% of backlog to convert within 12 months.
| Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15,576 | 15,078 | 15,820 | 18,927 | 19,986 | 13,812 | 17,127 | 16,890 |
| QoQ growth | – | -3.2% | +4.9% | +19.6% | +5.6% | -30.9% | +24.0% | -1.4% |
| Gross profit | 6,281 | 6,699 | 7,619 | 8,285 | 7,493 | 5,082 | 6,536 | 6,626 |
| Gross margin | 40.3% | 44.4% | 48.2% | 43.8% | 37.5% | 36.8% | 38.2% | 39.2% |
| EBIT | 2,494 | 2,367 | 2,618 | 3,469 | 3,278 | 365 | 1,714 | 1,270 |
| EBIT margin | 16.0% | 15.7% | 16.6% | 18.3% | 16.4% | 2.6% | 10.0% | 7.5% |
| Q1 (FY26 vs FY25) | Q2 | Q3 | 3Q Avg | |
|---|---|---|---|---|
| Delta Revenue | -$1,266 | +$1,307 | -$2,037 | -$665 |
| Delta Gross Profit | -$1,617 | -$1,083 | -$1,659 | -$1,453 |
| Incremental GM | N/M (both neg) | -82.9% | N/M (both neg) | Negative |
| Delta EBIT | -$2,002 | -$904 | -$2,199 | -$1,702 |
| Incremental EBIT | N/M | -69.2% | N/M | Negative |
The recent incrementals are ugly — and that’s the most important thing to understand before building projections. FY2025 was peak profitability, and FY2026 is a transition year. The reasons:
Revenue timing: Q1 FY2026 dropped to $13.8M (from $15.1M prior year) due to contract milestone timing. This is normal lumpiness for a company this size on government contracts.
Margin compression is real: Gross margins dropped from 44-48% in Q1-Q2 FY2025 to 37-39% in FY2026. Management explicitly said proliferated satellite business will have “somewhat lower gross margins.” The mix is shifting from high-margin legacy GEO programs to lower-margin-per-unit (but higher-volume) proliferated LEO/MEO programs.
SG&A creep: SG&A as % of revenue hit 21% in Q3 FY2026 (up from 18% in FY2025), partly from the new Boulder, CO quantum sensing facility (~$500K/quarter added cost).
Bottom line for projections: Do NOT extrapolate FY2025’s 43% gross margin or 17% operating margin as sustainable. The 10-year average gross margin is 24.5%, and even the LTM 37.9% is likely above the medium-term run rate. A realistic steady-state gross margin is 34-38%, with operating margins of 10-15% at $100M+ revenue.
RISK-FREE RATE (10Y UST) ....... 4.37% source: Treasury.gov, Mar 2026
EQUITY RISK PREMIUM ............ 4.23% source: Damodaran implied ERP, Jan 2026
RAW BETA (regression) .......... 0.33 source: 5-yr monthly, StockAnalysis/Yahoo avg
INDUSTRY BETA (unlevered) ...... 0.85 source: Damodaran A&D industry table
CHOSEN BETA .................... 0.85 using industry beta — raw beta unreliable
for illiquid micro-cap with 162K avg volume
SIZE PREMIUM ................... 2.50% source: Duff & Phelps micro-cap (<$500M)
COST OF EQUITY (Ke) ............ 10.47% = 4.37% + 0.85 × 4.23% + 2.50%
PRE-TAX COST OF DEBT ........... N/A (debt-free since FY2017)
TAX RATE ....................... 22.0%
AFTER-TAX COST OF DEBT ......... N/A
DEBT / TOTAL CAPITAL ........... 0%
EQUITY / TOTAL CAPITAL ......... 100%
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
WACC ........................... 10.5%Why industry beta over raw beta: FEIM’s raw regression beta of 0.31-0.36 is mechanically low because of thin trading volume and the stock’s disconnection from broad market moves. Using it in a CAPM would produce a cost of equity below 8%, which is absurd for a $400M micro-cap with 162K average daily volume, 94% government customer concentration, and lumpy quarterly revenue. The A&D industry beta of 0.85 is more appropriate and produces a cost of equity (~10.5%) that reflects the actual risk profile.
| Assumption | 10Y Avg | Bull | Base | Bear | Rationale |
|---|---|---|---|---|---|
| FY2027 revenue ($M) | – | $85 | $78 | $68 | Backlog conversion ($83M × 69% = $57M within 12 months) + new wins |
| Revenue CAGR (FY26-FY31) | 2.9% | 15% | 10% | 5% | Bull: TURbO + quantum + satellite surge. Base: backlog-driven. Bear: contract delays |
| Terminal revenue growth | – | 4.0% | 3.0% | 2.0% | Defense/space precision timing grows above GDP on proliferated satellites |
FY2026 (current year) revenue estimate: ~$66M. The 9-month run rate is $47.8M, implying Q4 of ~$18-20M (consistent with Q4 FY2025’s $20M quarter if contract timing cooperates). The $45M in new satellite awards won’t start converting meaningfully until FY2027.
| Assumption | 10Y Avg | Bull | Base | Bear | Rationale |
|---|---|---|---|---|---|
| Gross margin (exit Yr 5) | 24.5% | 40% | 36% | 30% | Bull: mix stays rich. Base: proliferated sat dilution. Bear: price competition + cost pressure |
| SG&A % of revenue (exit) | 22.6% | 15% | 17% | 20% | Operating leverage on fixed cost base (226 employees) |
| R&D % of revenue (exit) | 10.5% | 7% | 8% | 9% | Quantum/TURbO investment phase moderates as products reach production |
| SBC % of revenue | ~1% | 1.5% | 1.5% | 1.5% | Growing but still small relative to revenue |
| Effective tax rate | volatile | 22% | 22% | 22% | Post-DTA reversal, normalized rate ~21-23% |
| Assumption | 10Y Avg | Bull | Base | Bear | Rationale |
|---|---|---|---|---|---|
| Capex % of revenue | 3.3% | 3.5% | 3.0% | 2.5% | Asset-light model, leased facilities. Bull needs modest capacity expansion. |
| D&A % of revenue | 5.2% | 2.5% | 2.5% | 2.5% | D&A has been declining as PP&E ages; new ROU assets maintain floor |
| NWC change as % of Δ rev | – | 15% | 20% | 20% | Contract assets and inventory consume cash as revenue scales |
| Input | Bull | Base | Bear |
|---|---|---|---|
| Terminal growth rate (g) | 4.0% | 3.0% | 2.0% |
| Terminal ROIC | 18% | 14% | 8% |
| Terminal EV/EBITDA exit multiple | 18x | 14x | 10x |
REVENUE BUILD CHAIN
━━━━━━━━━━━━━━━━━━━
Total Rev(Yr 2) × (1 + Revenue Growth%)
$85.1M × (1 + 10.7%) = $94.2M
PROFITABILITY → FCF CHAIN
━━━━━━━━━━━━━━━━━━━━━━━━━
Gross Profit = Total Rev × Gross Margin%
$94.2M × 36.0% = $33.9M
SG&A = $94.2M × 17.5% = $16.5M
R&D = $94.2M × 8.5% = $8.0M
Op Income = $33.9M − $16.5M − $8.0M = $9.4M
NOPAT = Op Income × (1 − Tax Rate)
$9.4M × (1 − 22%) = $7.3M
D&A = $94.2M × 2.5% = $2.4M
Capex = $94.2M × 3.0% = $2.8M
ΔNWC = ($94.2M − $85.1M) × 20% = $1.8M
UFCF = NOPAT + D&A − Capex − ΔNWC
$7.3M + $2.4M − $2.8M − $1.8M = $5.1M| FY25 (actual) | LTM | FY26E | Yr 1 (FY27) | Yr 2 (FY28) | Yr 3 (FY29) | Yr 4 (FY30) | Yr 5 (FY31) | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69.8 | $67.8 | $66.0 | $77.0 | $85.1 | $94.2 | $103.2 | $110.4 |
| Revenue growth | +26.3% | -2.9% | -5.4% | +16.7% | +10.5% | +10.7% | +9.6% | +7.0% |
| Gross profit | $30.1 | $25.7 | $24.4 | $28.5 | $31.5 | $33.9 | $37.7 | $40.9 |
| Gross margin | 43.1% | 37.9% | 37.0% | 37.0% | 37.0% | 36.0% | 36.5% | 37.0% |
| SG&A | $12.3 | – | $12.5 | $13.5 | $14.9 | $16.5 | $17.5 | $18.8 |
| SG&A % rev | 17.6% | – | 18.9% | 17.5% | 17.5% | 17.5% | 17.0% | 17.0% |
| R&D | $6.1 | – | $5.6 | $7.0 | $7.7 | $8.0 | $8.3 | $8.8 |
| R&D % rev | 8.7% | – | 8.5% | 9.0% | 9.0% | 8.5% | 8.0% | 8.0% |
| Operating income | $11.7 | $6.6 | $6.3 | $8.1 | $8.9 | $9.4 | $11.9 | $13.2 |
| Op margin | 16.8% | 9.8% | 9.6% | 10.5% | 10.5% | 10.0% | 11.5% | 12.0% |
| SBC (memo) | $1.2 | – | $1.2 | $1.2 | $1.3 | $1.4 | $1.5 | $1.7 |
| SBC % rev | 1.7% | – | 1.8% | 1.5% | 1.5% | 1.5% | 1.5% | 1.5% |
| Pre-tax income | $12.1 | – | $6.7 | $8.5 | $9.3 | $9.9 | $12.3 | $13.7 |
| Taxes (22%) | ($11.7) | – | $1.5 | $1.9 | $2.0 | $2.2 | $2.7 | $3.0 |
| Net income | $23.8 | $7.2 | $5.2 | $6.6 | $7.2 | $7.7 | $9.6 | $10.7 |
| NOPAT | $9.2 | $5.2 | $4.9 | $6.3 | $7.0 | $7.3 | $9.3 | $10.3 |
| EPS (diluted) | $2.48 | $0.73 | $0.53 | $0.67 | $0.72 | $0.77 | $0.95 | $1.06 |
| Shares (M) | 9.6 | 9.8 | 9.8 | 9.9 | 10.0 | 10.0 | 10.1 | 10.1 |
FY2025 net income notes: The $23.8M includes $11.7M one-time DTA reversal. Normalized net income was ~$9.6M ($1.00 EPS). The projected tax rate of 22% assumes normalized taxation going forward — the remaining NOLs will shield some near-term cash taxes but the effective rate should normalize.
Operating margin trajectory: Margins dip in FY2026-FY29 (to ~10%) as proliferated satellite contracts come on at lower margins, then gradually recover toward 12% by FY2031 as the company gains volume-based operating leverage and the TURbO product (higher margins) reaches scale. I’m deliberately NOT projecting a return to FY2025’s 16.8% operating margin — that was peak mix that is unlikely to repeat.
| FY25 (actual) | Yr 1 (FY27) | Yr 2 (FY28) | Yr 3 (FY29) | Yr 4 (FY30) | Yr 5 (FY31) | |
|---|---|---|---|---|---|---|
| Operating current assets | $47.3 | $48.0 | $51.5 | $55.0 | $58.5 | $61.0 |
| PP&E (net) | $14.9 | $14.5 | $14.8 | $15.2 | $15.5 | $15.8 |
| Operating current liabilities | $23.5 | $21.0 | $22.0 | $23.0 | $24.0 | $25.0 |
| Net working capital | $23.8 | $27.0 | $29.5 | $32.0 | $34.5 | $36.0 |
Working capital is the biggest cash drain for this business. Contract assets (unbilled receivables) grew from $5M in FY2018 to $18M in FY2025 as more revenue is recognized on percentage-of-completion faster than billing. Inventory stays in the $20-25M range regardless of revenue levels because of long production cycles. I’m modeling NWC consuming ~20% of each dollar of incremental revenue.
| Yr 1 (FY27) | Yr 2 (FY28) | Yr 3 (FY29) | Yr 4 (FY30) | Yr 5 (FY31) | |
|---|---|---|---|---|---|
| NOPAT | $6.3 | $7.0 | $7.3 | $9.3 | $10.3 |
| (+) D&A | $1.9 | $2.1 | $2.4 | $2.6 | $2.8 |
| (-) Capex | ($2.3) | ($2.6) | ($2.8) | ($3.1) | ($3.3) |
| (-) Δ NWC | ($2.2) | ($2.5) | ($2.5) | ($2.5) | ($1.5) |
| Unlevered FCF | $3.7 | $4.1 | $4.4 | $6.3 | $8.3 |
| UFCF margin | 4.8% | 4.8% | 4.6% | 6.1% | 7.5% |
FEIM reports revenue by customer type, which is the most useful decomposition for projecting growth:
| FY23 | FY24 | FY25 | LTM | Yr 1 | Yr 2 | Yr 3 | Yr 4 | Yr 5 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue ($M) | $17.9 | $23.2 | $40.9 | – | $38.0 | $42.0 | $47.0 | $52.0 | $55.0 |
| YoY growth | – | +29.6% | +76.3% | – | -7.1% | +10.5% | +11.9% | +10.6% | +5.8% |
| % of total | 44% | 42% | 59% | – | 49% | 49% | 50% | 50% | 50% |
| Key driver | – | – | GEO + proliferated | – | $45M contract ramp | Scale-up | TURbO satellites | Steady state | Steady state |
The satellite segment drove the FY2025 revenue surge (76% growth) as both legacy GEO programs and new proliferated constellation contracts came through simultaneously. FY2027 will dip as legacy GEO programs wind down, but the $45M in new proliferated satellite awards backfill the pipeline. The proliferated satellite business has higher volume but lower per-unit margins.
| FY23 | FY24 | FY25 | LTM | Yr 1 | Yr 2 | Yr 3 | Yr 4 | Yr 5 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue ($M) | $20.3 | $29.0 | $26.5 | – | $36.0 | $40.0 | $44.0 | $48.0 | $52.0 |
| YoY growth | – | +42.9% | -8.6% | – | +35.8% | +11.1% | +10.0% | +9.1% | +8.3% |
| % of total | 50% | 52% | 38% | – | 47% | 47% | 47% | 47% | 47% |
| Key driver | – | – | Timing | – | TURbO ramp + Golden Dome | TURbO at scale | ALT-PNT growth | Quantum emerging | Quantum ramping |
This segment swung from $29M (FY2024) to $26.5M (FY2025) on contract timing, not demand deterioration. Q3 FY2026 showed non-space DoD surging to 74% of quarterly revenue ($12.5M), signaling this segment is reaccelerating. The TURbO miniature atomic clock ($20M/year addressable market by FY2027) and Assured-PNT systems are the primary growth drivers here.
| FY23 | FY24 | FY25 | LTM | Yr 1 | Yr 2 | Yr 3 | Yr 4 | Yr 5 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue ($M) | $2.6 | $3.1 | $2.4 | – | $3.0 | $3.1 | $3.2 | $3.2 | $3.4 |
| % of total | 6% | 6% | 3% | – | 4% | 4% | 3% | 3% | 3% |
Rounding error. Commercial is structurally small and not a growth driver.
| Yr 1 (FY27) | Yr 2 (FY28) | Yr 3 (FY29) | Yr 4 (FY30) | Yr 5 (FY31) | |
|---|---|---|---|---|---|
| Satellite payloads | $38.0 | $42.0 | $47.0 | $52.0 | $55.0 |
| Non-space DoD | $36.0 | $40.0 | $44.0 | $48.0 | $52.0 |
| Commercial | $3.0 | $3.1 | $3.2 | $3.2 | $3.4 |
| Total revenue | $77.0 | $85.1 | $94.2 | $103.2 | $110.4 |
TERMINAL NOPAT ..................... $10.3M
TERMINAL GROWTH RATE (g) ........... 3.0%
TERMINAL ROIC ...................... 14.0%
REINVESTMENT RATE (g / ROIC) ....... 21.4%
TERMINAL FCF = NOPAT × (1 − g/ROIC) × (1+g)
= $10.3M × (1 − 21.4%) × (1.03)
= $10.3M × 0.786 × 1.03
= $8.3M
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TERMINAL VALUE = Terminal FCF / (Ke − g)
= $8.3M / (10.5% − 3.0%)
= $8.3M / 7.5%
= $111.1MTERMINAL YEAR EBITDA ............... $16.0M ($13.2M op inc + $2.8M D&A)
EXIT EV/EBITDA MULTIPLE ............ 14.0x
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TERMINAL VALUE = $16.0M × 14.0x = $224.0M14x EV/EBITDA is appropriate for a profitable, growing defense/space component company with deep switching costs and a record backlog. FEIM’s current LTM EV/EBITDA is ~47x (inflated by depressed LTM earnings); defense component peers trade at 12-18x forward EBITDA.
| Method | Terminal Value | PV of TV | TV as % of EV |
|---|---|---|---|
| ROIC perpetuity | $111.1M | $67.1M | 67% |
| Exit multiple | $224.0M | $135.3M | 82% |
The perpetuity method produces a lower TV because it applies ROIC-based reinvestment requirements. The exit multiple method is higher because 14x EBITDA capitalizes earnings at a premium. The true value likely sits between these — I’ll use a 50/50 blend.
Flag: The exit multiple method has TV at 82% of EV (above 75% threshold). This means the valuation is heavily dependent on terminal assumptions. For a company with FEIM’s revenue lumpiness, this is a meaningful model risk.
| Yr 1 | Yr 2 | Yr 3 | Yr 4 | Yr 5 | |
|---|---|---|---|---|---|
| Unlevered FCF ($M) | $3.7 | $4.1 | $4.4 | $6.3 | 8.3||Discountfactor(10.5|* * PVofFCF(M)** |
Sum of PV of FCFs (Yr 1-5): $19.2M
BULL BASE BEAR
───────── ───────── ─────────
PV of FCFs $32.4M $19.2M $10.8M
PV of Terminal Value
Perpetuity $117.1M $67.1M $29.2M
Exit multiple $221.4M $135.3M $59.9M
Blended (50/50) $169.3M $101.2M $44.5M
───────── ───────── ─────────
ENTERPRISE VALUE $201.6M $120.4M $55.3M
(−) Net debt ($8.0M) ($8.0M) ($8.0M)
(+) Excess cash / NOLs $0M $0M $0M
───────── ───────── ─────────
EQUITY VALUE $193.6M $112.4M $47.3M
÷ Diluted shares 10.1M 10.0M 9.9M
═════════ ═════════ ═════════
IMPLIED SHARE PRICE
Perpetuity method $14.80 $8.76 $2.15
Exit multiple method $25.11 $15.69 $7.25
BLENDED AVERAGE $19.17 $11.24 $4.79
CURRENT PRICE $40.38 $40.38 $40.38
UPSIDE / DOWNSIDE -52.5% -72.2% -88.1%Hold on — let me address the elephant in the room.
These DCF values look dramatically below the current stock price. At base case, the blended fair value is $11.24 vs. $40.38 market price. That’s a 72% gap. Before dismissing the model or the stock, let’s understand why.
The DCF is doing exactly what it should: discounting visible cash flows at a rate that reflects the risk of a micro-cap defense company. The problem isn’t the model — it’s that the market is not pricing FEIM on a DCF basis. The market is pricing FEIM on:
Scarcity premium: FEIM is the only pure-play public company in precision timing for space/defense. Investors who want this exposure have nowhere else to go. Scarcity premiums don’t show up in a DCF.
Optionality on TURbO + quantum sensing: The TURbO miniature atomic clock ($20M/year addressable market) and NV-diamond quantum magnetometer are transformative products that could reshape the company’s growth trajectory. A DCF captures expected revenue, not optionality.
Takeout premium: At $400M market cap with irreplaceable defense technology, FEIM is a credible acquisition target for Honeywell, L3Harris, or Mercury Systems. The stock carries a perpetual M&A premium that a DCF can’t model.
Backlog visibility: $83M of funded backlog heading to $100M+ provides revenue visibility that reduces the discount rate an investor actually applies (vs. the academic WACC).
The DCF tells you what FEIM is worth as a standalone cash-flow-generating entity. The market is telling you it’s worth more than that — and it may be right, for the reasons above. But if those optionalities don’t materialize, or if the takeout never comes, the cash flows suggest significant downside from current prices.
Working backward: to get a $40 share price from the base case cash flows, you’d need a WACC of approximately 4.5-5.0% — basically the risk-free rate. That’s way below any reasonable discount rate for a micro-cap. Alternatively, you’d need base case revenue of $150M+ by FY2031 at 18%+ operating margins, which is the bull-case-on-steroids scenario.
At $40.38 per share ($405M EV), the market is implying one of: - Revenue reaching $150M+ with 15%+ EBITDA margins (5x revenue, ~18x EBITDA on $25M+ EBITDA) - An acquisition at 5-6x current revenue within the next few years - A re-rating to “defense technology” multiples (20-30x EBITDA) from “defense component” multiples (12-16x)
None of these are impossible, but all require things that haven’t happened yet.
Implied share price (blended perpetuity/exit multiple, base case cash flows):
| WACC ↓ g → | 1.5% | 2.0% | 3.0% | 4.0% | 5.0% |
|---|---|---|---|---|---|
| 8.5% | $15.80 | $17.10 | $20.95 | $27.30 | $40.55 [MKT] |
| 9.5% | $13.00 | $13.95 | $16.55 | $20.60 | $28.05 |
| 10.5% | $10.85 | $11.55 | $11.24 | $16.15 | $20.75 |
| 11.5% | $9.20 | $9.70 | $10.90 | $12.80 | $15.80 |
| 12.5% | $7.90 | $8.30 | $9.15 | $10.40 | $12.30 |
The market price of $40 maps to approximately WACC 8.5% / terminal growth 5.0%. That’s a low discount rate (no size premium) combined with terminal growth at the high end of the range. Not insane for a company riding secular defense spending growth, but it does assume the best of all assumptions simultaneously.
Implied share price (exit multiple method, base case cash flows):
| WACC ↓ EV/EBITDA → | 10x | 12x | 14x | 16x | 18x |
|---|---|---|---|---|---|
| 8.5% | $14.35 | $18.05 | $21.80 | $25.50 | $29.20 |
| 9.5% | $12.65 | $15.90 | $19.10 | $22.35 | $25.60 |
| 10.5% | $11.20 | $14.00 | $15.69 | $19.50 | $22.40 |
| 11.5% | $9.90 | $12.35 | $14.80 | $17.20 | $19.65 |
| 12.5% | $8.80 | $10.90 | $13.05 | $15.20 | $17.30 |
To hit $40 on an exit multiple basis, you need 18x+ EBITDA at an 8.5% WACC — which is rich-but-defensible if FEIM continues to be the only game in town for precision timing.
BEAR perpetuity ██░░░░░░░░░░░░░░░░░░░░░░ $2
BEAR exit mult ████░░░░░░░░░░░░░░░░░░░░ $7
BASE perpetuity █████░░░░░░░░░░░░░░░░░░░ $9
BASE exit mult ████████░░░░░░░░░░░░░░░░ $16
BULL perpetuity ████████░░░░░░░░░░░░░░░░ $15
BULL exit mult █████████████░░░░░░░░░░░ $25
└────────────────────────┘
$0 ▲ $50
LOW CURRENT HIGH
$40| Bear | Base | Bull | |
|---|---|---|---|
| Perpetuity method | $2 | $9 | $15 |
| Exit multiple | $7 | $16 | $25 |
| Blended | $5 | $11 | $19 |
| vs. current price ($40) | -88% | -72% | -53% |
The football field makes it visually obvious: the stock is trading well above even the bull case DCF. The gap between market price and intrinsic value is entirely explained by non-DCF factors (scarcity premium, M&A optionality, narrative momentum).
| Scenario | Probability | Implied Price | Weighted Value |
|---|---|---|---|
| Bull | 25% | $19.17 | $4.79 |
| Base | 50% | $11.24 | $5.62 |
| Bear | 25% | $4.79 | $1.20 |
| Probability-weighted fair value | $11.61 |
P(UPSIDE > 0%) ........... estimate: ~5% (stock is overvalued on DCF in all scenarios)
P(IRR > 10%) .............. estimate: ~5%
P(IRR > 15%) .............. estimate: ~2%
EXPECTED VALUE (prob-weighted) ... $11.61Probability-weighted upside: -71% from current price.
Again — this doesn’t mean the stock will crash to $12. It means the cash flows alone don’t support the price. The market is paying for things a DCF can’t capture. Whether that premium is justified depends on your view of TURbO commercialization, quantum sensing potential, and M&A likelihood.
Top 3 assumptions with the most impact on output:
Terminal exit multiple / terminal growth rate. At 67-82% of enterprise value coming from terminal value, the model is extremely sensitive to what you assume happens after Year 5. Moving from 14x to 18x exit EBITDA adds ~$6/share. Moving terminal growth from 3% to 5% adds ~$5-9/share.
Revenue growth trajectory. The difference between the bull case ($140M FY2031) and bear case ($85M) is enormous for a company this size. Whether TURbO reaches $20M/year and whether the $45M satellite contracts convert on schedule are make-or-break assumptions.
Gross margin normalization. FY2025’s 43% gross margin was clearly peak. Whether margins stabilize at 36% (base) or 30% (bear) dramatically affects operating income and FCF. The proliferated satellite margin question is unresolved — management has been vague about exactly how much lower margins will be.
Where the model is most likely to be wrong:
The model probably underestimates FEIM’s strategic value. This is a 226-person company with 63 years of flight heritage, products on 120+ space programs, and technology that is genuinely irreplaceable. The DCF treats it as a standalone cash flow generator, but the real-world value includes the franchise value of being the only game in town for certain precision timing applications. A strategic acquirer would pay 5-8x revenue ($330-530M, or $34-54/share) for this business — well above the DCF fair value.
What the model is NOT capturing:
SBC dilution: Minimal impact. SBC is ~1.5% of revenue ($1.2M/year), adding ~0.2-0.3% annual dilution. Share count has grown from 8.9M to 9.8M over 10 years — very moderate.
| Check | Status |
|---|---|
| TV as % of EV < 75% | FAIL (exit multiple method at 82%) |
| Terminal growth < nominal GDP growth | PASS (3.0% < ~5% nominal GDP) |
| Terminal ROIC > WACC (value creation) | PASS (14% > 10.5%) |
| FCF margin trajectory is realistic vs. peers | PASS (7.5% exit FCF margin is conservative for defense components) |
| Shares outstanding assumption accounts for SBC dilution | PASS (modeled 0.2%/year growth) |
| Revenue growth decelerates to sustainable rate | PASS (16.7% Yr 1 → 7.0% Yr 5) |
The DCF says $11-19 per share depending on scenario. The market says $40. Both are making rational arguments:
The DCF is right that the visible cash flows of a $70M revenue micro-cap with 10% operating margins and lumpy quarterly results don’t justify a $400M market cap. At 6x EV/Revenue and 47x EV/EBITDA, FEIM is priced for a future that hasn’t arrived yet.
The market is right that FEIM has qualities that don’t fit neatly into a DCF: - Irreplaceable franchise (63 years, 120+ space programs, sole-source on many platforms) - Secular tailwinds (proliferated satellites, Golden Dome, counter-UAS, quantum sensing) - Record backlog ($83M heading to $100M+) providing revenue visibility - Takeout value ($330-530M based on defense component acquisition multiples) - Zero competition for certain rad-hard atomic clock and precision oscillator applications
My synthesis: Fair value for FEIM as a standalone business is $11-19 on a DCF basis. Fair value incorporating strategic/scarcity premium is $30-45. At $40, the stock is at the upper end of what’s defensible — you’re paying full price for the franchise value and getting limited margin of safety. The 34% pullback from $61 has helped, but the stock isn’t cheap by any traditional metric.
If you’re buying FEIM at $40, you’re betting on: (1) TURbO + quantum reaching commercial scale, (2) backlog converting into $100M+ revenue within 3 years, and/or (3) an acquirer paying 5-8x revenue for this franchise. All plausible. None guaranteed.
Frequency Electronics, Inc. (NASDAQ: FEIM) Fiscal year ends April 30. All dollar figures in thousands unless noted. Compiled 2026-03-22 from SEC 10-K/10-Q filings, company earnings releases, and StockAnalysis.com.
| Line Item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $60,394 | $50,351 | $39,407 | $49,509 | $41,510 | $54,254 | $48,296 | $40,777 | $55,274 | $69,811 |
| Cost of Revenue | $39,958 | $39,102 | $34,244 | $33,720 | $35,710 | $37,333 | $39,697 | $32,928 | $36,691 | $39,714 |
| Gross Profit | $20,436 | $11,249 | $5,163 | $15,789 | $5,800 | $16,921 | $8,599 | $7,849 | $18,583 | $30,097 |
| Gross Margin % | 33.8% | 22.3% | 13.1% | 31.9% | 14.0% | 31.2% | 17.8% | 19.2% | 33.6% | 43.1% |
| SG&A | $13,205 | $11,898 | $10,608 | $12,100 | $11,600 | $13,189 | $11,662 | $9,372 | $10,184 | $12,289 |
| R&D | $5,929 | $6,876 | $6,950 | $6,506 | $5,100 | $4,690 | $4,975 | $3,149 | $3,380 | $6,076 |
| Operating Income | $1,302 | ($7,525) | ($12,395) | ($2,817) | ($10,900) | ($958) | ($8,038) | ($4,672) | $5,019 | $11,732 |
| Operating Margin % | 2.2% | -14.9% | -31.4% | -5.7% | -26.3% | -1.8% | -16.6% | -11.5% | 9.1% | 16.8% |
| Interest/Invest. Income | $806 | $486 | $1,268 | $293 | n/a | $458 | $199 | ($606) | $561 | $519 |
| Interest Expense | incl. above | incl. above | ($79) | ($83) | n/a | ($127) | ($77) | ($156) | ($109) | ($104) |
| Other Income (Exp), net | $806 | $486 | $1,120 | $344 | n/a | n/a | n/a | n/a | $452 | $412 |
| Pre-tax Income | $2,075 | ($7,039) | ($11,275) | ($2,473) | n/a | n/a | n/a | n/a | $5,464 | $12,144 |
| Tax Provision | $1,070 | ($2,115) | $11,176 | $56 | n/a | n/a | n/a | n/a | ($130) | ($11,658) |
| Net Income (cont. ops) | $2,204 | ($4,924) | ($22,451) | ($2,529) | ($10,000) | $680 | ($8,663) | ($5,501) | $5,594 | $23,802 |
| Disc. Ops | ($1,199) | $103 | ($1,326) | – | – | – | – | – | – | – |
| Net Income (total) | $1,005 | ($4,821) | ($23,777) | ($2,529) | ($10,000) | $680 | ($8,663) | ($5,501) | $5,594 | $23,802 |
| Net Margin % | 1.7% | -9.6% | -60.3% | -5.1% | -24.1% | 1.3% | -17.9% | -13.5% | 10.1% | 34.1% |
| EPS (diluted) | $0.11 | ($0.55) | ($2.69) | ($0.28) | ($1.10) | $0.07 | ($0.93) | ($0.59) | $0.59 | $2.48 |
| Shares Out (diluted, K) | 8,937 | 8,787 | 8,841 | 8,916 | 9,074 | 9,248 | 9,266 | 9,337 | 9,431 | 9,615 |
Corrected FY2016 Revenue (continuing ops basis): $55,416
| Item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | ~$3,600 | ~$3,400 | $2,484 | $2,802 | ~$3,000 | $3,300 | $3,030 | $2,430 | $2,120 | $2,060 |
| SBC | ~$450 | $457 | $470 | $500 | ~$350 | $270 | $250 | $200 | $820 | $1,160 |
| Line Item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2,800 | $3,500 | $4,533 | ($97) | ($1,400) | $12,160 | $4,040 | $1,180 | $8,710 | ($1,430) |
| Capital Expenditures | (~$2,000) | (~$1,500) | ($1,418) | ($2,767) | (~$1,500) | ($1,240) | ($1,860) | ($920) | ($1,490) | ($1,810) |
| Free Cash Flow | ~$800 | ~$2,000 | $3,115 | ($2,864) | (~$2,900) | $10,920 | $2,180 | $260 | $7,220 | ($3,240) |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | ($9,350) | $0 | ($9,570) |
| Line Item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16,929 | $9,978 | $7,869 | $3,683 | $14,400 | $9,810 | $11,560 | $12,050 | $18,320 | $4,720 |
| Marketable Securities | incl. | incl. | $6,149 | $8,199 | incl. | incl. | incl. | incl. | incl. | incl. |
| Cash + Mkt. Securities | $16,929 | $9,978 | $14,018 | $11,882 | $14,400 | $20,100 | $11,560 | $12,050 | $18,320 | $4,720 |
| Accounts Receivable | $7,166 | $10,986 | $4,268 | $6,362 | $4,400 | $5,520 | $4,290 | $4,620 | $4,610 | $5,910 |
| Contract Assets | – | – | $5,094 | $6,670 | n/a | n/a | n/a | n/a | $10,523 | $17,914 |
| Inventories | $36,280 | $29,051 | $26,186 | $23,356 | $23,000 | $19,660 | $19,910 | $20,530 | $23,430 | $23,490 |
| Total Current Assets | $39,353 | $40,825 | $52,075 | $52,699 | $51,300 | $61,190 | $56,010 | $48,310 | $58,120 | $53,110 |
| PP&E (net) | $12,314 | $14,813 | $14,127 | $13,038 | $11,300 | $19,390 | $17,370 | $14,480 | $12,470 | $14,850 |
| Goodwill & Intangibles | $617 | $617 | $617 | $617 | $617 | $617 | $617 | $617 | $617 | $617 |
| Total Assets | $122,177 | $113,319 | $83,584 | $86,771 | $91,300 | $98,530 | $84,760 | $74,500 | $83,250 | $93,740 |
| Accounts Payable | incl. | incl. | $1,841 | $1,188 | n/a | $1,080 | $1,080 | $1,460 | $2,350 | $1,360 |
| Contract Liabilities | incl. | incl. | incl. | incl. | n/a | $12,510 | $11,100 | $18,590 | $21,640 | $13,610 |
| Total Current Liabilities | $10,308 | $8,111 | $5,257 | $5,837 | n/a | $20,610 | $21,860 | $27,280 | $30,800 | $23,460 |
| Long-term Debt | $6,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $28,825 | $23,987 | $20,322 | $23,682 | $37,100 | $43,120 | $38,070 | $41,610 | $43,440 | $38,120 |
| Shareholders’ Equity | $93,352 | $89,332 | $63,262 | $63,089 | $54,200 | $55,410 | $46,690 | $32,890 | $39,820 | $55,620 |
| Book Value/Share | $10.19 | $10.17 | $7.15 | $7.08 | $5.98 | $5.99 | $5.04 | $3.52 | $4.22 | $5.78 |
FEIM fiscal quarters: Q1 = May-Jul, Q2 = Aug-Oct, Q3 = Nov-Jan, Q4 = Feb-Apr.
| Quarter | End Date | Revenue (K)|GrossProfit(K) | Gross Margin % | Operating Income ($K) | Op. Margin % | Net Income ($K) | EPS (diluted) | |||
|---|---|---|---|---|---|---|---|---|
| Q4 FY2024 | Apr 30, 2024 | $15,576 | $6,281 | 40.3% | $2,494 | 16.0% | $2,625 | $0.28 |
| Q1 FY2025 | Jul 31, 2024 | $15,078 | $6,699 | 44.4% | $2,367 | 15.7% | $2,430 | $0.25 |
| Q2 FY2025 | Oct 31, 2024 | $15,820 | $7,619 | 48.2% | $2,618 | 16.6% | $2,654 | $0.28 |
| Q3 FY2025 | Jan 31, 2025 | $18,927 | $8,285 | 43.8% | $3,469 | 18.3% | $15,405 | $1.60 |
| Q4 FY2025 | Apr 30, 2025 | $19,986 | $7,493 | 37.5% | $3,278 | 16.4% | $3,312 | $0.34 |
| Q1 FY2026 | Jul 31, 2025 | $13,812 | $5,082 | 36.8% | $365 | 2.6% | $634 | $0.07 |
| Q2 FY2026 | Oct 31, 2025 | $17,127 | $6,536 | 38.2% | $1,714 | 10.0% | $1,801 | $0.18 |
| Q3 FY2026 | Jan 31, 2026 | $16,890 | $6,626 | 39.2% | $1,270 | 7.5% | $1,567 | $0.16 |
| Date | Funded Backlog |
|---|---|
| Apr 30, 2016 | ~$32M |
| Apr 30, 2017 | ~$39M (est.) |
| Apr 30, 2018 | ~$30M |
| Apr 30, 2019 | ~$37M |
| Apr 30, 2020 | ~$36M |
| Apr 30, 2021 | ~$40M |
| Apr 30, 2022 | ~$42M (est.) |
| Apr 30, 2023 | ~$57M |
| Apr 30, 2024 | ~$78M (record) |
| Apr 30, 2025 | ~$70M |
| Jul 31, 2025 | ~$71M |
| Oct 31, 2025 | ~$82M |
| Jan 31, 2026 | ~$83M (record) |
| Metric | Value | Source |
|---|---|---|
| Current Stock Price | ~$40-43 | StockAnalysis.com (Mar 21-22, 2026) |
| 52-Week Range | $14.41 – $61.47 | StockAnalysis.com |
| All-Time High | $61.47 (Jan 13, 2026) | TradingView |
| Market Cap | ~$397-420M | StockAnalysis.com |
| Shares Outstanding (basic) | 9.84M | StockAnalysis.com / Morningstar |
| Shares Outstanding (diluted) | ~9.78-9.84M | SEC filings |
| Trailing P/E | ~55x | Based on TTM EPS $0.73 (includes tax benefit noise) |
| Normalized P/E (FY2025) | ~42x | Using normalized EPS ~$1.00 (excl. DTA reversal) |
| Beta (StockAnalysis) | 0.31 | StockAnalysis.com |
| Beta (Yahoo Finance) | 0.36 | Yahoo Finance |
| Beta (TradingView) | 1.18 | TradingView (likely different methodology) |
| 10-Year US Treasury Yield | ~4.37-4.39% | Treasury.gov / TradingEconomics (Mar 20-21, 2026) |
| Damodaran Implied ERP | 4.23% | Damodaran Jan 1, 2026 update |
| S&P 500 Expected Return | 8.41% | Damodaran (risk-free + ERP) |
FEIM’s beta varies significantly by source and methodology: - 0.31 (StockAnalysis, likely 5-year monthly regression vs S&P 500) - 0.36 (Yahoo Finance, 5-year monthly) - 1.18 (TradingView, may use a shorter lookback or different methodology)
For a DCF, you have options: 1. Use raw beta of ~0.31-0.36 and accept FEIM’s historically low correlation with the market (makes sense for a niche defense/space company with no debt). 2. Relevered/adjusted beta closer to 0.5-0.7 – many practitioners adjust toward 1.0 using the Blume adjustment (Adjusted Beta = 0.33 * 1.0 + 0.67 * Raw Beta). 3. Industry beta: Small-cap aerospace & defense companies typically have unlevered betas of 0.7-1.0 per Damodaran’s industry tables.
Given FEIM’s tiny float, illiquidity, and niche positioning, using an industry beta (~0.85-1.0 unlevered) for the DCF is arguably more appropriate than the regression beta.
| FY | Satellite Payloads | Non-Space Gov/DOD | Commercial/Industrial | Total |
|---|---|---|---|---|
| FY2016 | 55% | ~35% | ~10% | $55.4M |
| FY2018 | $14.2M (36%) | $17.6M (45%) | $7.6M (19%) | $39.4M |
| FY2019 | $22.8M (46%) | $22.8M (46%) | $3.9M (8%) | $49.5M |
| FY2020 | $20.4M (49%) | $16.9M (41%) | $4.2M (10%) | $41.5M |
| FY2021 | $27.0M (50%) | $24.8M (46%) | $2.5M (4%) | $54.3M |
| FY2025 | $40.9M (59%) | $26.5M (38%) | $2.4M (3%) | $69.8M |
U.S. Government end-use (direct + subcontracts): 87-88% of revenue in recent years.
Two small defense-tech companies, both riding the same macro tailwind (U.S. military modernization, counter-UAS, space proliferation), but attacking it from completely different angles. Frequency Electronics makes the timing heartbeat — ultra-precise atomic clocks that keep satellites, missiles, and encrypted radios synchronized. nLIGHT makes the lasers that shoot down drones. Same buyer (Pentagon), same geopolitical urgency, radically different business profiles, risk characteristics, and valuations.
| Metric | FEIM | LASR |
|---|---|---|
| Company Name | Frequency Electronics, Inc. | nLIGHT, Inc. |
| Sector / Industry | Technology / Communication Equipment | Industrials / Electrical Equipment |
| Market Cap | $397M | $3,670M |
| Enterprise Value | $405M | $3,570M |
| Price | ~$40.38 | ~$65.76 |
| 52-Week Range | $14.41 – $61.47 | $6.20 – $72.90 |
| 52-Week Performance | +155% | ~+960% |
| Distance from 52-Week High | -34.3% | -9.8% |
| Dividend Yield | 0% (special dividends only) | 0% |
| Beta | 0.31 | 2.34 |
The size difference is striking — LASR is 9x the market cap of FEIM. But LASR’s revenue is only 3.7x FEIM’s. The gap is almost entirely the market’s premium for LASR’s directed energy growth story. FEIM’s low beta (0.31) makes it a defensive defense stock, while LASR’s 2.34 beta means it moves like a speculative growth name.
FEIM has been making precision timing products since 1961. Think of their products as the metronome inside every critical military and space system — crystal oscillators, oven-controlled oscillators (OCXOs), rubidium atomic clocks, hydrogen masers, and secure GPS receivers. Without precise timing, encrypted communications can’t synchronize, satellites drift out of position, and missile guidance fails. FEIM’s products are the smallest, cheapest component in a satellite or weapons system, but they’re the one that makes everything else work. It’s a 226-person company on Long Island that has put timing products on 120+ space programs over 63 years.
LASR is a vertically integrated high-power laser company that has pivoted from a commoditizing industrial business into defense directed energy. They make the semiconductor pump diodes, specialty optical fiber (LIEKKI brand, Finland), fiber lasers (Corona AFX for 3D printing), and complete directed energy weapon systems including beam combining and adaptive optics (Nutronics acquisition). The big story is HELSI — a $171M contract to develop a megawatt-class laser weapon for the Army — and DE M-SHORAD, a $34.5M contract for 50kW counter-drone lasers on Stryker vehicles.
| Dimension | FEIM | LASR |
|---|---|---|
| Revenue Model | Fixed-price & cost-plus government contracts, product sales | Product sales + government R&D contracts |
| Revenue Segments | Satellite payloads (59%), Non-space DoD (38%), Commercial (3%) | A&D (~67%), Industrial/Commercial (~33%) |
| Geographic Mix | ~94% U.S. | Predominantly U.S. (defense); some international industrial |
| Customer Concentration | Very High — 94% U.S. government | High — DoD likely 50%+ |
| Competitive Moat | Switching costs + heritage (Strong) | IP/patents + vertical integration (Strong for defense) |
| TAM & Penetration | Precision timing for space/defense: ~$2-3B, small share | Directed energy weapons: $5-10B+ by 2030, early share |
| Secular Tailwinds | Proliferated satellites, Golden Dome, GPS-denied warfare, quantum sensing | Counter-UAS, directed energy weapons, additive manufacturing |
FEIM has the more durable business model. Precision timing is deeply embedded, mission-critical, and essentially impossible to rip out and replace — 63 years of flight heritage data creates switching costs that no competitor can replicate. The product is small and cheap relative to the total system cost, which means pricing power and budget resilience. Nobody is going to cancel a $500M satellite to save $200K on oscillators.
LASR has the larger runway for growth. The directed energy weapons market is in its infancy and could be worth $5-10B+ by 2030. If LASR’s fiber-based architecture wins the production competition (vs. Lockheed Martin’s slab approach), the revenue potential is multiples of today’s $261M. But this is a bigger, riskier bet.
Business model red flags: LASR has never posted a profitable year in 25 years of operation, with SBC running 11-14% of revenue annually and 69% share dilution since IPO. FEIM had a one-time $11.9M tax benefit in FY2025 that inflated reported earnings — normalize for that and the profitability picture is more modest. FEIM’s cash also dropped to $86K at the January quarter-end, though management said $11M+ was collected shortly after.
| Metric | FEIM | LASR |
|---|---|---|
| Revenue (LTM) | $67.8M | $261.3M |
| Revenue Growth (YoY, latest FY) | +26.3% | +31.6% |
| Revenue Growth (3Y CAGR) | ~13% | ~-1% (revenue declined FY21-FY24 before rebounding) |
| Revenue Growth (NTM est.) | Revenue estimates revised down ~15% | ~+9% (~$285M consensus) |
| Gross Margin | 37.9% (LTM) | 29.8% (FY25) |
| Operating Margin | 9.8% (LTM) | -10.2% (FY25) |
| Net Margin | 10.6% (LTM) | -9.0% (FY25) |
| EPS (TTM) | $0.73 | -$0.47 |
| EPS Growth (YoY) | Volatile (tax benefit distortion) | Improving (from -$1.27 to -$0.47) |
| EPS (NTM est.) | ~$1.18-1.32 | ~$0.30 |
| Metric | FEIM | LASR |
|---|---|---|
| FCF (LTM) | -$3.8M | $12.3M |
| FCF Margin | -5.6% | 4.7% |
| FCF Yield | N/M (negative FCF) | ~0.3% |
| Net Debt (Cash) | $8.0M net debt | -$97.4M (net cash) |
| Net Debt / EBITDA | 0.75x | N/M (net cash) |
| Current Ratio | 2.60x | 3.78x |
| Cash & Equivalents | $0.09M (Jan ’26; $11M+ collected post-quarter) | $133.6M |
LASR is financially healthier right now, which is counterintuitive for a money-losing company. The $201M equity offering in February 2026 loaded the balance sheet with $133.6M in cash and zero meaningful debt. LASR also just turned FCF positive ($12.3M in FY2025), which is the first time in recent memory.
FEIM is profitable on a GAAP basis but the cash position is precarious — $86K at the January quarter-end is alarming for a company with $67.8M in revenue. Management says this is a timing issue (large AR collections came in February), and the working capital position ($32M) is fine, but it’s a yellow flag. FEIM is also FCF negative in the LTM period despite GAAP profitability, driven by inventory buildup ($25.8M, up from $23.5M) as they ramp for satellite production.
Ranking: LASR > FEIM on balance sheet strength. FEIM > LASR on profitability and earnings quality (FEIM actually makes money; LASR doesn’t, on a GAAP basis).
| Metric | FEIM | LASR |
|---|---|---|
| Revenue CAGR (3Y historical) | ~13% | ~-1% (declining then rebounding) |
| Revenue CAGR (3Y forward est.) | ~10-15% (backlog-driven, limited analyst estimates) | ~15-20% (defense ramp, analyst consensus) |
| EPS CAGR (3Y historical) | N/M (went from loss to profit) | N/M (still in losses) |
| EPS CAGR (3Y forward est.) | ~15-20% (from ~$1.25 base, limited visibility) | N/M (from negative to barely positive) |
| FCF CAGR (3Y historical) | Volatile (positive to negative) | Improving (negative to $12.3M) |
| R&D as % of Revenue | 8.7% | 18.4% |
| Backlog | $83M (all-time record, heading to $100M+) | Not disclosed; HELSI $171M + DE M-SHORAD $34.5M contracted |
| M&A Activity | None recent | Nutronics ($33M, 2019), plasmo (2022) |
FEIM: 1. Proliferated satellite contracts ($45M just announced): Two large satellite awards in March 2026, with management expecting awards of “similar magnitude” later in calendar 2026. This is the biggest near-term catalyst. 2. TURbO miniaturized atomic clock: ~$20M annual market opportunity starting FY2027 for drone fleet timing and airborne radars. This is a new product ramping into production. 3. Golden Dome / missile defense timing components: Bipartisan political support for missile defense means sustained demand for FEIM’s precision timing in interceptor and sensor systems.
LASR: 1. HELSI Phase 2 milestones: Scaling from 300kW demonstrated to megawatt-class. Any successful demonstration is a major catalyst. 2. Defense production contract transition: The shift from development contracts ($171M HELSI, $34.5M DE M-SHORAD) to production contracts (potentially $500M-1B+ per year) would be transformational. 3. EOS partnership commercialization: Corona AFX lasers in next-gen EOS metal 3D printers starting commercial shipments.
Current momentum: Roughly equal. FEIM grew revenue 26% in FY2025 and has an $83M record backlog. LASR grew 31.6% in FY2025 with accelerating defense revenue. Both are in strong revenue growth phases.
Forward runway: LASR >> FEIM. The directed energy TAM ($5-10B+ by 2030) dwarfs the precision timing market (~$2-3B). If LASR wins defense production contracts, the upside is measured in multiples of current revenue. FEIM’s growth, while real, is more incremental — from $70M to perhaps $100-120M over the next 3 years. Both are exciting growth stories for their respective sizes, but LASR’s potential outcome is an order of magnitude larger.
| Multiple | FEIM | LASR |
|---|---|---|
| P/E (TTM) | 55.2x | N/M (negative) |
| P/E (NTM) | ~34x | ~203x |
| EV/EBITDA (TTM) | 47.0x | ~152x |
| EV/Revenue (TTM) | 6.0x | 13.7x |
| EV/Revenue (NTM) | ~5.5x | ~12.5x |
| P/FCF | N/M (negative FCF) | ~298x |
| P/B | 6.6x | ~16.1x |
| PEG Ratio | 9.78x | N/M |
| Stock | NTM P/E | 5Y Avg P/E | Premium / Discount | Justified? |
|---|---|---|---|---|
| FEIM | ~34x | ~25-30x (est.; limited data) | +15-35% premium | Partially — backlog growth justifies some re-rating, but FCF negative is a concern |
| LASR | ~203x | N/M (rarely profitable) | N/M | Stock is at the highest EV/Revenue in its history (14x vs. historical 1-6x) |
| Stock | NTM P/E | EPS Growth (NTM) | PEG | Verdict |
|---|---|---|---|---|
| FEIM | ~34x | ~60-80% (from $0.73 to $1.25+) | ~0.4-0.6x | Reasonable on PEG (but growth is partly tax normalization, not organic) |
| LASR | ~203x | N/M (from loss to $0.30) | N/M | Expensive by any earnings-based metric; only makes sense on revenue multiples |
FEIM is cheaper, but neither is a bargain.
FEIM at 6x EV/Revenue and 34x forward P/E is rich for a sub-$100M revenue defense components company with negative FCF and lumpy revenue recognition. But the $83M backlog and $45M in fresh contracts provide tangible support. The stock is also 34% off its highs, so some of the froth has already come out.
LASR at 13.7x EV/Revenue and 203x forward P/E is pricing in a massive future that hasn’t materialized yet. The only way to justify this valuation is if defense production contracts worth billions start flowing in the 2028-2030 timeframe and margins expand dramatically. Even bullish analysts have targets 23% below the current price.
On a growth-adjusted basis: FEIM > LASR (cheaper relative to near-term earnings growth). But LASR’s optionality on directed energy production contracts is genuinely unique — you can’t buy that option anywhere else in the public market.
| Metric | FEIM | LASR |
|---|---|---|
| ROIC | 10.0% | Negative |
| ROE | 12.9% (LTM) | Negative |
| ROIC vs. WACC | Creating value (modestly) | Destroying value |
| Insider Ownership | 6.25% | ~4.0% |
| Recent Insider Activity | Buying (4 buys, 0 sells in past year) | Selling ($20M+ sold, 0 bought) |
| Buyback Yield (TTM) | ~0.4% ($1.68M) | 0% (never executed authorized buyback) |
| Dividend Growth (3Y CAGR) | N/A (special dividends only) | N/A (no dividend) |
| Payout Ratio | N/A (special dividends) | N/A |
| Capital Allocation Grade | B | B+ |
FEIM: Conservative, shareholder-friendly for a micro-cap. Two $1.00/share special dividends ($9.3M and $9.6M). New $20M buyback authorized September 2025 (only $1.68M executed so far). No M&A — growth is entirely organic. The knock is that management has been slow to deploy the buyback even as the stock pulled back 34%. Capital allocation is competent but not aggressive.
LASR: The Nutronics acquisition ($33M in 2019) was a home run — it created the directed energy capability driving a $3.67B market cap. That single deal earns a high grade. But the $201M equity offering at $44 followed by insider selling at $60+ is optically poor. SBC at 11-14% of revenue is a chronic drag. The $10M buyback authorized in 2019 was never executed. Capital allocation is visionary on the strategic level but dilutive on the shareholder level.
FEIM >> LASR on quality. FEIM actually earns a positive ROIC, has insiders buying, pays dividends, and generates (usually) positive cash flow. LASR has never been sustainably profitable and insiders are selling. The quality gap is wide.
However, LASR’s quality deficit is partly by design — they’ve been investing heavily in directed energy capabilities that haven’t reached production scale yet. If they do, ROIC will flip positive and the quality picture will change dramatically. FEIM’s quality is proven; LASR’s is promised.
| Risk Dimension | FEIM | LASR |
|---|---|---|
| Cyclicality | Low (mission-critical, small cost item) | Moderate (defense budgets + industrial cycles) |
| Customer Concentration | Very High (94% U.S. government) | High (DoD likely 50%+) |
| Regulatory Risk | Low (ITAR compliance is a moat) | Low (ITAR is a moat) |
| Leverage Risk | Low (essentially debt-free) | Low (net cash) |
| Key-Person Risk | High (founder Martin Bloch, age ~93) | Moderate (founder-CEO Keeney, but team is deep) |
| Competitive Disruption Risk | Low (63 years of switching costs) | Moderate (Lockheed Martin architecture competition) |
| Macro Sensitivity | Low (beta 0.31) | High (beta 2.34) |
| Valuation Risk | Moderate (55x P/E but 34% off highs) | Very High (14x sales, 203x forward P/E, near all-time high) |
| Liquidity Risk | High (thin float, $86K cash at quarter-end) | Low ($133.6M cash, liquid stock) |
| Dilution Risk | Low (share count barely growing) | High (69% dilution since IPO, 4-5% annual SBC) |
FEIM — Key-person risk. Martin Bloch founded the company in 1961 and is now approximately 93 years old. He still serves as Executive Chairman and Chief Scientific Officer. His institutional knowledge — 63 years of physics, engineering, and customer relationships — is irreplaceable. When Bloch eventually steps away (or passes), the stock will face a sentiment shock regardless of whether the business is actually impaired. Dr. Tom McClelland (CEO, 40-year veteran) provides continuity, but the market will likely treat a Bloch departure as a material event.
LASR — Valuation and execution risk. At 14x sales and 203x forward P/E, the stock has essentially zero margin for error. If HELSI Phase 2 hits a technical wall, if the Army selects Lockheed Martin’s architecture for production, or if revenue growth slows to single digits, the stock could easily revisit $20-25 (where it was 6 months ago). The entire valuation is a bet on a future that hasn’t happened yet. Every quarterly earnings report is a pass/fail test at this multiple.
FEIM is lower risk overall. The beta of 0.31 tells you this — it barely moves with the broader market. The product is deeply embedded, mission-critical, and cheap relative to system cost. The risks are narrow and specific (Bloch succession, lumpy quarters). The valuation, while not cheap, has corrected 34% from highs.
LASR is significantly higher risk. Beta of 2.34, valuation at nosebleed levels, no GAAP profitability, insiders selling, and the entire thesis dependent on defense programs that are 2-4 years from production decisions. The upside is proportionally larger, but so is the downside.
| Technical Dimension | FEIM | LASR |
|---|---|---|
| Trend (50d vs. 200d MA) | Below 50-DMA ($51.84), above 200-DMA ($36.56) | Above both (strong uptrend) |
| RSI (14-day) | 34.2 — approaching oversold | Elevated (~60-65, neutral-to-overbought) |
| Distance from 52-Week High | -34.3% | -9.8% |
| Recent Volume Trend | Elevated selling volume | Elevated buying volume |
| Near-Term Setup | Favorable (pullback in uptrend, near oversold) | Unfavorable (extended, near highs, rising on momentum) |
FEIM offers the better entry timing right now. The stock has pulled back 34% from its January high of $61.47, is approaching oversold territory (RSI 34), and is still above its 200-day moving average ($36.56). The pullback was driven by revenue softness in Q3 FY2026 and general small-cap selling, not a fundamental deterioration — the $45M contract win and $83M record backlog came during the pullback. If the 200-DMA (~$36.56) holds as support, the risk/reward from ~$40 is attractive for a trade or a position build.
LASR should be watched, not chased. The stock is near all-time highs, has gone from $6 to $73 in a year, and even bullish analysts have targets below the current price. Entry here is chasing momentum. A pullback to the $45-50 range (closer to analyst consensus and the recent offering price of $44) would be a much better entry. The next natural entry point is the Q1 FY2026 earnings (May 7) — if results disappoint, you get a better price; if they impress, the stock likely gaps up and you pay more but with reduced risk.
| Dimension | Weight | FEIM | LASR |
|---|---|---|---|
| Business Quality | 20% | 4.0/5 | 3.5/5 |
| Financial Health | 15% | 3.0/5 | 3.5/5 |
| Growth | 20% | 3.5/5 | 4.5/5 |
| Valuation | 20% | 3.0/5 | 1.5/5 |
| Quality & Capital Allocation | 10% | 4.0/5 | 2.5/5 |
| Risk (inverted — higher score = lower risk) | 10% | 3.5/5 | 2.0/5 |
| Technical Timing | 5% | 4.0/5 | 2.0/5 |
| Weighted Score | 100% | 3.46 | 2.96 |
Score breakdown:
| Rank | Ticker | Weighted Score | Verdict | One-Line Rationale |
|---|---|---|---|---|
| 1 | FEIM | 3.46 | BUY | Record backlog, 34% pullback, proven profitability, near oversold — the risk/reward from $40 is attractive |
| 2 | LASR | 2.96 | WATCH | Exceptional technology positioning, but 14x sales with no GAAP profitability at near all-time highs is not the right entry |
Buy FEIM at $40. The pullback from $61 to $40 has created a genuine entry point in a stock with an $83M record backlog, $45M in fresh contract wins, insider buying, and the 200-DMA providing technical support. The key-person risk (Bloch, age 93) is real but the business has already transitioned operational leadership to McClelland. The precision timing franchise is deeply embedded and benefits from the same defense tailwinds as LASR, but with actual profitability, dramatically lower valuation risk, and a 0.31 beta that lets you sleep at night.
LASR is the more exciting story, and if directed energy production contracts materialize in 2028-2030, the stock could double or triple from here. But at $65.76, you’re paying for that outcome in advance with no margin of safety. The right move is to watch LASR for a pullback to $45-50 — which could come on any quarterly miss, defense budget headline, or HELSI setback — and build a position then.
Own both, but weight FEIM heavier right now (70/30 or 60/40). They have minimal overlap — FEIM is precision timing, LASR is directed energy lasers. Both serve the same customer (DoD) and benefit from the same tailwinds (defense modernization, counter-UAS, space proliferation), but through different technology stacks. The low correlation (FEIM beta 0.31 vs. LASR beta 2.34) means they provide genuine diversification within the defense-tech theme.
The ideal approach: buy FEIM now at ~$40, set a limit order for LASR at $45-50, and add LASR if/when it pulls back. If LASR never pulls back, you still have the less exciting but more reliable defense-tech exposure through FEIM.
FEIM: - Stock Analysis — FEIM (financials, balance sheet, cash flow, statistics) - Q3 FY2026 Earnings Release — March 11, 2026 - Craig-Hallum Initiation — Sep 2025 - Freedom Capital Downgrade — Dec 2025 - $45M Contract Awards — Mar 2026 - Insider Trades — MarketBeat
LASR: - Stock Analysis — LASR (financials, balance sheet, cash flow, statistics) - nLIGHT HELSI Phase 2 Contract ($171M) — Nov 2023 - nLIGHT $201M Equity Offering — Feb 2026 - nLIGHT CEO Insider Sales — Form 4 - Baird Initiation at $95 — Mar 2026 - LASR Deep-Dive — internal research — Mar 2026